ACD856, a novel positive allosteric modulator of Trk receptors, single ascending doses in healthy subjects: Safety and pharmacokinetics
European Journal of Clinical Pharmacology · 2024-05 · 80 (5) · 717-727
DOI: 10.1007/s00228-024-03645-1 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Clinical Pharmacology, online erschienen am 14.02.2024. Verfasst von Boel Nilsson und 6 weiteren Autor:innen. Beteiligte Einrichtung: AlzeCure Pharma AB, Hälsovägen 7, SE-141 57, Huddinge, Sweden. Hauptthemen laut MEDLINE: Healthy Volunteers. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Karolinska Institute.
Abstract (Originalsprache)
Purpose
AlzeCure Pharma AB is developing novel positive allosteric modulators of Trk-receptors for treatment of Alzheimer’s disease, depression, other psychiatric conditions and other disorders where cognition is impaired. The preceding candidate drug ACD855 was shown to have a too long half-life in humans to allow further development. To de-risk the development of the follow-up compound ACD856, the oral single ascending dose study of ACD856 in humans was preceded by an intravenous microdose study, assessing the elimination half-life in plasma.
Methods
A phase 0 study with a microdose of ACD856 (0.100 mg), was conducted in six healthy male subjects all receiving ACD856. Sequentially, a randomized, placebo-controlled, double-blind Phase I single ascending oral dose study (1 – 150 mg) was conducted, including 56 healthy subjects. Both studies assessed the safety and tolerability, as well as the PK properties of ACD856 after single dose intravenous and oral administration.
Results
ACD856 was well tolerated with no treatment emergent, or dose related adverse events or other safety assessments. In the microdose study, ACD856 exhibited a bi-exponential plasma decline, low distribution volume, low plasma clearance with a half-life of approximately 20 hours. Orally, ACD856 exhibited rapid absorption, an almost complete bioavailability and a dose proportional increase in exposure. While the C max was lowered and delayed by food intake, the effect on plasma half-life and the overall bioavailability was low. No renal elimination of ACD856 was detected.
Conclusion
The prediction proved accurate demonstrating the value of conducting a microdose study prior to ascending dose studies.
Trial registration
NCT05783830 March 24, 2023 (microdose study, retrospectively registered) and NCT05077631 October 14, 2021 (single ascending dose study).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- AlzeCure Pharma AB, Hälsovägen 7, SE-141 57, Huddinge, Sweden.
- CTC Clinical Trial Consultants AB, Dag Hammarskjölds väg 10B, SE-752 37, Uppsala, Sweden.
- Department of Surgical Sciences, Plastic Surgery, Uppsala University, SE-751 85, Uppsala, Sweden.
- AlzeCure Pharma AB, Hälsovägen 7, SE-141 57, Huddinge, Sweden. marta.segerdahl@alzecurepharma.com.
- Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Alfred Nobels allé 23, SE-141 52, Huddinge, Sweden. marta.segerdahl@alzecurepharma.com.
Förderung
- Karolinska Institute
Zitieren
APA
Nilsson, B., Bylund, J., Halldin, M. M., Rother, M., Rein-Hedin, E., Önnestam, K., & Segerdahl, M. (2024). ACD856, a novel positive allosteric modulator of Trk receptors, single ascending doses in healthy subjects: Safety and pharmacokinetics. European Journal of Clinical Pharmacology, 80(5), 717-727. https://doi.org/10.1007/s00228-024-03645-1
Vancouver
Nilsson B, Bylund J, Halldin MM, Rother M, Rein-Hedin E, Önnestam K, et al. ACD856, a novel positive allosteric modulator of Trk receptors, single ascending doses in healthy subjects: Safety and pharmacokinetics. European Journal of Clinical Pharmacology. 2024;80(5):717-727. doi:10.1007/s00228-024-03645-1
BibTeX
@article{Nilsson2024,
author = {Nilsson, Boel and Bylund, Johan and Halldin, Magnus M and Rother, Matthias and Rein-Hedin, Erik and Önnestam, Kristin and Segerdahl, Märta},
title = {ACD856, a novel positive allosteric modulator of Trk receptors, single ascending doses in healthy subjects: Safety and pharmacokinetics},
journal = {European Journal of Clinical Pharmacology},
year = {2024},
volume = {80},
number = {5},
pages = {717--727},
doi = {10.1007/s00228-024-03645-1}
}
EUVIMED